vs
渤健（BIIB）与PILGRIMS PRIDE CORP（PPC）财务数据对比。点击上方公司名可切换其他公司
PILGRIMS PRIDE CORP的季度营收约是渤健的2.0倍（$4.5B vs $2.3B），PILGRIMS PRIDE CORP净利率更高（1.9% vs -2.1%，领先4.1%），PILGRIMS PRIDE CORP同比增速更快（3.3% vs -7.1%），渤健自由现金流更多（$468.0M vs $10.0M），过去两年PILGRIMS PRIDE CORP的营收复合增速更高（1.8% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Pilgrim's Pride是美国跨国食品企业，为美国及波多黎各最大的鸡肉生产商之一，同时是墨西哥第二大鸡肉生产商。公司2009年12月脱离破产状态，2011年将美国总部迁至科罗拉多州格里利，由JBS集团控股，2016年11月底以3.5亿美元收购Gold'n Plump。
BIIB vs PPC — 直观对比
营收规模更大
PPC
是对方的2.0倍
$2.3B
营收增速更快
PPC
高出10.5%
-7.1%
净利率更高
PPC
高出4.1%
-2.1%
自由现金流更多
BIIB
多$458.0M
$10.0M
两年增速更快
PPC
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $4.5B |
| 净利润 | $-48.9M | $88.0M |
| 毛利率 | 78.3% | 9.5% |
| 营业利润率 | -2.5% | 4.5% |
| 净利率 | -2.1% | 1.9% |
| 营收同比 | -7.1% | 3.3% |
| 净利润同比 | -118.3% | -62.7% |
| 每股收益（稀释后） | $-0.35 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBPPC
| Q4 25 | $2.3B | $4.5B | ||
| Q3 25 | $2.5B | $4.8B | ||
| Q2 25 | $2.6B | $4.8B | ||
| Q1 25 | $2.4B | $4.5B | ||
| Q4 24 | $2.5B | $4.4B | ||
| Q3 24 | $2.5B | $4.6B | ||
| Q2 24 | $2.5B | $4.6B | ||
| Q1 24 | $2.3B | $4.4B |
净利润BIIBPPC
| Q4 25 | $-48.9M | $88.0M | ||
| Q3 25 | $466.5M | $342.8M | ||
| Q2 25 | $634.8M | $355.5M | ||
| Q1 25 | $240.5M | $296.0M | ||
| Q4 24 | $266.7M | $235.9M | ||
| Q3 24 | $388.5M | $349.9M | ||
| Q2 24 | $583.6M | $326.3M | ||
| Q1 24 | $393.4M | $174.4M |
毛利率BIIBPPC
| Q4 25 | 78.3% | 9.5% | ||
| Q3 25 | 73.4% | 13.9% | ||
| Q2 25 | 77.1% | 15.0% | ||
| Q1 25 | 74.1% | 12.4% | ||
| Q4 24 | 76.2% | 12.7% | ||
| Q3 24 | 74.1% | 14.9% | ||
| Q2 24 | 77.8% | 15.2% | ||
| Q1 24 | 76.3% | 8.8% |
营业利润率BIIBPPC
| Q4 25 | -2.5% | 4.5% | ||
| Q3 25 | 22.0% | 10.4% | ||
| Q2 25 | 28.1% | 10.8% | ||
| Q1 25 | 12.8% | 9.1% | ||
| Q4 24 | 11.9% | 7.0% | ||
| Q3 24 | 18.3% | 11.1% | ||
| Q2 24 | 28.3% | 9.7% | ||
| Q1 24 | 20.3% | 5.7% |
净利率BIIBPPC
| Q4 25 | -2.1% | 1.9% | ||
| Q3 25 | 18.4% | 7.2% | ||
| Q2 25 | 24.0% | 7.5% | ||
| Q1 25 | 9.9% | 6.6% | ||
| Q4 24 | 10.9% | 5.4% | ||
| Q3 24 | 15.8% | 7.6% | ||
| Q2 24 | 23.7% | 7.2% | ||
| Q1 24 | 17.2% | 4.0% |
每股收益（稀释后）BIIBPPC
| Q4 25 | $-0.35 | $0.37 | ||
| Q3 25 | $3.17 | $1.44 | ||
| Q2 25 | $4.33 | $1.49 | ||
| Q1 25 | $1.64 | $1.24 | ||
| Q4 24 | $1.82 | $1.00 | ||
| Q3 24 | $2.66 | $1.47 | ||
| Q2 24 | $4.00 | $1.37 | ||
| Q1 24 | $2.70 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $640.2M |
| 总债务越低越好 | $6.3B | $3.1B |
| 股东权益账面价值 | $18.3B | $3.7B |
| 总资产 | $29.4B | $10.3B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资BIIBPPC
| Q4 25 | — | $640.2M | ||
| Q3 25 | — | $612.6M | ||
| Q2 25 | — | $849.0M | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $870.8M |
总债务BIIBPPC
| Q4 25 | $6.3B | $3.1B | ||
| Q3 25 | $6.3B | $3.1B | ||
| Q2 25 | $6.3B | $3.1B | ||
| Q1 25 | $4.5B | $3.2B | ||
| Q4 24 | $6.3B | $3.2B | ||
| Q3 24 | $4.5B | $3.2B | ||
| Q2 24 | $6.3B | $3.2B | ||
| Q1 24 | $6.3B | $3.3B |
股东权益BIIBPPC
| Q4 25 | $18.3B | $3.7B | ||
| Q3 25 | $18.2B | $3.5B | ||
| Q2 25 | $17.6B | $3.7B | ||
| Q1 25 | $17.0B | $3.1B | ||
| Q4 24 | $16.7B | $4.2B | ||
| Q3 24 | $16.4B | $4.2B | ||
| Q2 24 | $15.9B | $3.7B | ||
| Q1 24 | $15.2B | $3.5B |
总资产BIIBPPC
| Q4 25 | $29.4B | $10.3B | ||
| Q3 25 | $29.2B | $10.0B | ||
| Q2 25 | $28.3B | $10.1B | ||
| Q1 25 | $28.0B | $11.0B | ||
| Q4 24 | $28.0B | $10.7B | ||
| Q3 24 | $28.3B | $10.7B | ||
| Q2 24 | $26.8B | $10.1B | ||
| Q1 24 | $26.6B | $9.8B |
负债/权益比BIIBPPC
| Q4 25 | 0.34× | 0.84× | ||
| Q3 25 | 0.35× | 0.87× | ||
| Q2 25 | 0.36× | 0.83× | ||
| Q1 25 | 0.27× | 1.02× | ||
| Q4 24 | 0.38× | 0.76× | ||
| Q3 24 | 0.28× | 0.76× | ||
| Q2 24 | 0.40× | 0.85× | ||
| Q1 24 | 0.41× | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $291.2M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $10.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 0.2% |
| 资本支出强度资本支出/营收 | 1.9% | 6.2% |
| 现金转化率经营现金流/净利润 | — | 3.31× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $653.1M |
8季度趋势，按日历期对齐
经营现金流BIIBPPC
| Q4 25 | $511.9M | $291.2M | ||
| Q3 25 | $1.3B | $458.3M | ||
| Q2 25 | $160.9M | $495.2M | ||
| Q1 25 | $259.3M | $126.9M | ||
| Q4 24 | $760.9M | $349.3M | ||
| Q3 24 | $935.6M | $651.1M | ||
| Q2 24 | $625.8M | $718.6M | ||
| Q1 24 | $553.2M | $271.0M |
自由现金流BIIBPPC
| Q4 25 | $468.0M | $10.0M | ||
| Q3 25 | $1.2B | $275.9M | ||
| Q2 25 | $134.3M | $339.1M | ||
| Q1 25 | $222.2M | $28.1M | ||
| Q4 24 | $721.6M | $176.6M | ||
| Q3 24 | $900.6M | $565.3M | ||
| Q2 24 | $592.3M | $617.7M | ||
| Q1 24 | $507.3M | $171.9M |
自由现金流率BIIBPPC
| Q4 25 | 20.5% | 0.2% | ||
| Q3 25 | 48.4% | 5.8% | ||
| Q2 25 | 5.1% | 7.1% | ||
| Q1 25 | 9.1% | 0.6% | ||
| Q4 24 | 29.4% | 4.0% | ||
| Q3 24 | 36.5% | 12.3% | ||
| Q2 24 | 24.0% | 13.5% | ||
| Q1 24 | 22.1% | 3.9% |
资本支出强度BIIBPPC
| Q4 25 | 1.9% | 6.2% | ||
| Q3 25 | 1.8% | 3.8% | ||
| Q2 25 | 1.0% | 3.3% | ||
| Q1 25 | 1.5% | 2.2% | ||
| Q4 24 | 1.6% | 4.0% | ||
| Q3 24 | 1.4% | 1.9% | ||
| Q2 24 | 1.4% | 2.2% | ||
| Q1 24 | 2.0% | 2.3% |
现金转化率BIIBPPC
| Q4 25 | — | 3.31× | ||
| Q3 25 | 2.73× | 1.34× | ||
| Q2 25 | 0.25× | 1.39× | ||
| Q1 25 | 1.08× | 0.43× | ||
| Q4 24 | 2.85× | 1.48× | ||
| Q3 24 | 2.41× | 1.86× | ||
| Q2 24 | 1.07× | 2.20× | ||
| Q1 24 | 1.41× | 1.55× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
PPC
| Retail | $1.5B | 33% |
| Europe Reportable Segment | $1.4B | 31% |
| Food Service | $889.2M | 20% |
| Prepared Product | $332.8M | 7% |
| Product Export | $122.7M | 3% |
| Other Sales Channel | $96.0M | 2% |
| Other Product And Service | $79.7M | 2% |
| Related Party | $21.7M | 0% |
| Seara Meats B.V. | $18.9M | 0% |
| Penasul UKLTD | $10.3M | 0% |
| JBSUSA Food Company | $5.4M | 0% |
